4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
JW (Cayman) Therapeutics Co. Ltd (2126) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 303 employees. Its market capitalization is roughly HK$1 billion. In the fiscal year ended 2025-12-31, 2126 reported CNY 284M in revenue and (CNY 555M) in net income.
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China.
Interactive charts & full statements → Open the 2126 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 284M | CNY 158M | CNY 174M | CNY 146M | — |
| Gross Profit | CNY 173M | CNY 77M | CNY 88M | CNY 59M | — |
| Operating Income (EBIT) | (CNY 242M) | (CNY 459M) | (CNY 570M) | (CNY 696M) | — |
| Net Income | (CNY 555M) | (CNY 591M) | (CNY 768M) | (CNY 846M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 987M | CNY 1.7B | CNY 2.1B | CNY 2.8B | — |
| Total Liabilities | CNY 431M | CNY 511M | CNY 462M | CNY 437M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2126 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms